Trametinib represents potential new standard-of-care for patients with recurrent low-grade serous ovarian carcinoma
A study has reported that the MEK inhibitor trametinib reduced the risk of disease progression or death by 52% compared to standard-of-care therapies for the treatment of low-grade serous ovarian carcinoma.
Materials provided by University of Texas M. D. Anderson Cancer Center. Note: Content may be edited for style and length.
Source link aaaaa